Floatz logo

Docetaxel

Esophageal Carcinoma

NuCana plcSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
81/ 100

Competitive context

40 Active assets in the Esophageal Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
NuCana plc
Phase 3BB
Irinotecan
Merck Sharp & Dohme LLC
Phase 3B
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493
National Cancer Institute (NCI)
Phase 2CCC
Defactinib
National Cancer Institute (NCI)
Phase 2CCC
TRASTUZUMAB
National Cancer Institute (NCI)
Phase 2CCC

View all 50 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →